Immune Checkpoint Inhibitors for Patients Aged  ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis

ConclusionsICIs appear to be effective in patients aged  ≥ 75 years. However, the survival benefit is mainly observed in first-line treatment and remains unclear in the second-line setting.
Source: Drugs and Aging - Category: Geriatrics Source Type: research